Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series.

Authors

Melissa D Svoboda
Nancy Kuntz
Carmen Leon-Astudillo
Barry J Byrne
Jena Krueger, Corewell Health West
Jennifer M Kwon
Cory Sieburg
Diana Castro

Document Type

Article

Publication Date

2-20-2026

Publication Title

Advances in Therapy

Abstract

This Summary of Research summarizes a previously published original article, "Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series." Spinal muscular atrophy (SMA) is a rare genetic disease that causes muscle weakness and is associated with swallowing and breathing difficulties. Risdiplam (EVRYSDI

Recommended Citation

Svoboda MD, Kuntz N, Leon-Astudillo C, Byrne BJ, Krueger J, Kwon JM, et al. Summary of research: Risdiplam treatment following onasemnogene abeparvovec in individuals with spinal muscular atrophy: A multicenter case series. Adv Ther. 2026. doi: 10.1007/s12325-026-03509-3. PMID: 41718941.

Comments

Helen DeVos Children's Hospital

DOI

10.1007/s12325-026-03509-3

ISSN

1865-8652

PubMed ID

41718941